KADMON CORPORATION, LLC – Trademark Portfolio

Entity Type: 16

KADMON CORPORATION, LLC holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include KADMON and RIBAPAK. The owner is based in Bridgewater, NJ.

55 Corporate Drive

Bridgewater, NJ 08807

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

RIBAONE
RIBAONE
Abandoned 2013
RIBADAY
RIBADAY
Abandoned 2013
RIBAONE
RIBAONE
Abandoned 2013
RIBADAY
RIBADAY
Abandoned 2013
KADMON
KADMON
Registered 2010
KADMON
KADMON
Registered 2010
RIBAPAK
RIBAPAK
Registered 2005

Trademark Classifications

KADMON CORPORATION, LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does KADMON CORPORATION, LLC have?

KADMON CORPORATION, LLC has 9 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned, 2 cancelled.

What trademark classes does KADMON CORPORATION, LLC file in?

KADMON CORPORATION, LLC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are KADMON CORPORATION, LLC's most well-known trademarks?

KADMON CORPORATION, LLC's registered trademark portfolio includes well-known marks such as KADMON and RIBAPAK. These are among 3 currently registered trademarks in the portfolio.

What is KADMON CORPORATION, LLC's trademark registration success rate?

KADMON CORPORATION, LLC has a 33% trademark registration rate, with 3 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.